Bioblast Pharma Ltd (ORPN)

1.41
0.04 2.76
NASDAQ : Health Care
Prev Close 1.45
Open 1.44
Day Low/High 1.40 / 1.44
52 Wk Low/High 1.53 / 7.95
Volume 3.67K
Avg Volume 44.50K
Exchange NASDAQ
Shares Outstanding 16.39M
Market Cap 23.11M
EPS -1.10
P/E Ratio 1.31
Div & Yield N.A. (N.A)

Latest News

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioBlast Pharma To Present Final HOPEMD Phase 2 Clinical Study Results Of Trehalose In Oculopharyngeal Muscular Dystrophy At The American Academy Of Neurology (AAN) 2016 Annual Meeting

BioBlast Pharma To Present Final HOPEMD Phase 2 Clinical Study Results Of Trehalose In Oculopharyngeal Muscular Dystrophy At The American Academy Of Neurology (AAN) 2016 Annual Meeting

Final Results of 24-Week Open-Label Phase 2 Trial Will be Presented by Professor Zohar Argov, MD, Senior Medical Advisor to BioBlast Pharma

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakouts.

BioBlast Pharma Enhances Leadership Team

BioBlast Pharma Enhances Leadership Team

Appoints Industry Veteran, Robert W. Cook, as Chief Financial Officer

BioBlast Scant Data Links Drug to Improved Swallowing in Patients

BioBlast Scant Data Links Drug to Improved Swallowing in Patients

BioBlast paints a very optimistic picture of Cabaletta's potential as an effective treatment for OPMD, but the data announced Tuesday are scant, cherry-picked and hardly conclusive.

BioBlast Pharma Augments Leadership Team

BioBlast Pharma Augments Leadership Team

Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer

BioBlast Pharma Augments Leadership Team And Establishes U.S. Headquarters In New Haven, Connecticut

BioBlast Pharma Augments Leadership Team And Establishes U.S. Headquarters In New Haven, Connecticut

Appoints Former NPS and ViroPharma Executive, Paul Firuta as Chief Commercial Officer